Contraline Inc.
Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company
This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.
